14
Participants
Start Date
March 1, 2012
Primary Completion Date
June 1, 2013
Study Completion Date
June 1, 2013
PF03446962
PF-03446962 will be administered in 1hr intravenously at a dose of 10 mg/Kg on day 1, then every 2 weeks until the evidence of disease progression or onset of unacceptable toxicity.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
OTHER